12/13
10:47 am
bioa
2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole [Yahoo! Finance]
Medium
Report
2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole [Yahoo! Finance]
12/8
06:44 pm
bioa
Leqembi included in China's commercial insurance innovative drug list
Medium
Report
Leqembi included in China's commercial insurance innovative drug list
12/8
06:42 pm
bioa
Leqembi included in China's commercial insurance innovative drug list
Medium
Report
Leqembi included in China's commercial insurance innovative drug list
12/6
01:36 am
bioa
12/6
01:36 am
bioa
12/5
01:54 pm
bioa
BioAge Labs (NASDAQ:BIOA) was upgraded by analysts at Morgan Stanley from an "underweight" rating to an "equal weight" rating. They now have a $12.00 price target on the stock.
Medium
Report
BioAge Labs (NASDAQ:BIOA) was upgraded by analysts at Morgan Stanley from an "underweight" rating to an "equal weight" rating. They now have a $12.00 price target on the stock.
12/4
10:58 am
bioa
BioAge Labs BGE-102 Phase 1 Trial Shows Potential in Targeting Inflammation in Central Nervous System, Peripheral Tissues [Yahoo! Finance]
Low
Report
BioAge Labs BGE-102 Phase 1 Trial Shows Potential in Targeting Inflammation in Central Nervous System, Peripheral Tissues [Yahoo! Finance]
12/4
09:00 am
bioa
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
High
Report
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
12/4
02:18 am
bioa
New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment
High
Report
New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment
12/4
02:13 am
bioa
New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment
High
Report
New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment
11/25
06:03 pm
bioa
BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
Medium
Report
BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
11/25
04:30 pm
bioa
BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference
Medium
Report
BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference
11/13
06:51 pm
bioa
Leqembi® approved for IV maintenance treatment in the United Kingdom
Low
Report
Leqembi® approved for IV maintenance treatment in the United Kingdom
11/13
06:50 pm
bioa
Leqembi® approved for IV maintenance treatment in the United Kingdom
Low
Report
Leqembi® approved for IV maintenance treatment in the United Kingdom
11/7
09:00 am
bioa
BioAge Labs to Present at Jefferies Global Healthcare Conference in London
Low
Report
BioAge Labs to Present at Jefferies Global Healthcare Conference in London
11/6
06:10 pm
bioa
BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates [Yahoo! Finance]
Low
Report
BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates [Yahoo! Finance]
11/6
04:45 pm
bioa
BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates
Low
Report
BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates
11/4
04:29 am
bioa
Invitation to presentation of BioArctic's third quarter report for July - September 2025 on November 13 at 9.30 a.m. CET
Low
Report
Invitation to presentation of BioArctic's third quarter report for July - September 2025 on November 13 at 9.30 a.m. CET
11/4
04:25 am
bioa
Invitation to presentation of BioArctic's third quarter report for July - September 2025 on November 13 at 9.30 a.m. CET
Low
Report
Invitation to presentation of BioArctic's third quarter report for July - September 2025 on November 13 at 9.30 a.m. CET
10/30
12:25 pm
bioa
BioAge Labs (NASDAQ:BIOA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
BioAge Labs (NASDAQ:BIOA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/29
10:09 am
bioa
BioAge Labs (NASDAQ:BIOA) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
BioAge Labs (NASDAQ:BIOA) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
10/26
10:58 pm
bioa
Health Canada Grants Authorization for Leqembi® (lecanemab)
Low
Report
Health Canada Grants Authorization for Leqembi® (lecanemab)
10/26
10:56 pm
bioa
Health Canada Grants Authorization for Leqembi® (lecanemab)
Low
Report
Health Canada Grants Authorization for Leqembi® (lecanemab)
10/14
03:30 am
bioa
First patient treated with Leqembi® (lecanemab) in the Nordics
Low
Report
First patient treated with Leqembi® (lecanemab) in the Nordics
10/14
01:18 am
bioa
Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025
Low
Report
Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025